RxDoctor Payments Data

Mark Adame, MD

Family Medicine · Salinas, CANPI 1346245669

Payments from drug & device makers

$4,588in general payments, 2019–2025

Across 242 payments — averaging $18.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$805
  • GSK$553
  • Novo Nordisk$547
  • Pfizer$388
  • Otsuka America Pharmaceutical, Inc.$313
  • AstraZeneca$296
  • plus $2K from 32 others

What the payments were for

  • Food & beverage$4,588100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,588 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$85,299
Medicare patients
306
Services billed
1,148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin60$54,562
MounjaroTirzepatide32$42,401
OzempicSemaglutide39$35,644
EliquisApixaban26$33,606
JanuviaSitagliptin Phosphate29$19,219
LinzessLinaclotide12$14,627
Colchicine11$4,211
Levothyroxine Sodium261$3,122
Atorvastatin Calcium315$2,993
SynthroidLevothyroxine Sodium29$2,350
Pantoprazole Sodium193$2,218
Rosuvastatin Calcium141$2,084
Olmesartan Medoxomil104$2,080
Albuterol Sulfate HfaAlbuterol Sulfate72$1,813
Metformin Hcl193$1,609

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$155$54,56260 claims
Lilly USA, LLCMounjaro$153$42,40132 claims
Novo NordiskOzempic$547$35,64439 claims
PfizerEliquis$388$33,60626 claims
MerckJanuvia$88$19,21929 claims
AbbVieLinzess, Synthroid$805$16,97741 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Salinas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →